Date published: 2025-9-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

FSD1L Inhibitors

FSD1L inhibitors are a class of chemical compounds that target and inhibit the activity of the enzyme FSD1-like protein (FSD1L). FSD1L is a member of the F-box protein family, which is involved in various cellular processes, primarily through its role in ubiquitin-mediated protein degradation. F-box proteins serve as part of the SCF (SKP1-Cullin-F-box) complex, a type of E3 ubiquitin ligase complex, which facilitates the recognition and ubiquitination of specific substrates, leading to their proteasomal degradation. By inhibiting FSD1L, these compounds disrupt its involvement in this regulatory pathway, potentially leading to alterations in protein turnover and intracellular signaling pathways. FSD1L inhibitors are designed to specifically bind to this protein, thereby preventing its interaction with other components of the SCF complex and reducing its ability to target proteins for ubiquitination.

The inhibition of FSD1L activity has been shown to have significant implications on various biological processes due to its role in maintaining protein homeostasis. Disrupting this function can lead to an accumulation of proteins that would normally be degraded, thereby affecting cell cycle regulation, apoptosis, and other critical cellular activities. FSD1L inhibitors are typically developed with chemical structures that allow them to bind selectively to the active sites or key regions of the FSD1L protein, ensuring specific inhibition. Researchers study the structural properties of these inhibitors to optimize their binding affinity and stability. Through detailed molecular and biochemical studies, these compounds are often characterized for their effects on FSD1L activity, substrate interaction, and the broader implications for protein regulation within the cell.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

An mTOR inhibitor that can suppress cell growth and proliferation, potentially downregulating FSD1L expression if it is linked to these cell processes.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

A PI3K inhibitor that can disrupt downstream signaling, possibly affecting FSD1L if it is involved in the PI3K/Akt pathway.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

A MEK inhibitor that can interfere with the MAPK/ERK pathway, potentially altering FSD1L expression or function if it is regulated by this pathway.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$65.00
$267.00
257
(3)

A JNK inhibitor that can modulate the JNK signaling pathway, possibly affecting FSD1L activity or stability if it is associated with stress response signaling.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

A p38 MAPK inhibitor that can inhibit p38-mediated signaling pathways, potentially impacting FSD1L if it plays a role in inflammation or stress responses.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

A PI3K inhibitor similar to LY294002, which can alter cellular growth and survival signaling, potentially affecting FSD1L activity.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

A MEK inhibitor that selectively inhibits ERK activation, potentially leading to changes in FSD1L regulation if linked to the ERK pathway.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$182.00
$693.00
88
(1)

A ROCK inhibitor that inhibits Rho-associated protein kinase, potentially affecting FSD1L if it is involved in cytoskeletal organization.

PP 2

172889-27-9sc-202769
sc-202769A
1 mg
5 mg
$92.00
$223.00
30
(1)

A Src family kinase inhibitor that can disturb various signaling pathways, potentially altering FSD1L activity if it is linked to Src signaling.

BIX 02189

1094614-85-3sc-364436
sc-364436A
5 mg
10 mg
$220.00
$378.00
5
(1)

A MEK5 inhibitor that can affect the MEK5/ERK5 pathway, potentially influencing FSD1L if it is regulated by this pathway.